HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015

被引：0
作者：
Bourlière M. [1 ]
Asselah T. [2 ]
机构：
[1] Department of Hepato-Gastroenterology, Hospital Saint Joseph, Marseilles
[2] Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, 100 Bd du Général Leclerc, Clichy
来源：
Current Hepatology Reports | 2015年 / 14卷 / 4期
关键词：
Daclatasvir; Dasabuvir; Elbasvir; Grazoprevir; Ledipasvir; Ombitasvir; Paritaprevir; Sofosbuvir;
D O I：
10.1007/s11901-015-0282-6
中图分类号：
学科分类号：
摘要：
There is a revolution in the treatment of chronic hepatitis C with several oral regimen with direct-acting antivirals (DAAs) being developed, increasing sustained virological success rates and shortened treatment duration. In 2014–2015, combinations of DDAs with additive potency that lack cross-resistance and with a good safety profile may provide new regimens to make hepatitis C virus (HCV) the first chronic viral infection eradicated worldwide. The aim of this review is to summarize results from approved or available complete phase III clinical trials obtained with oral DAAs combination, regimen available in 2015 in several countries for genotype 1 patients. © 2015, Springer Science+Business Media New York.
引用
收藏
页码：260 / 266
页数：6
相关论文
共 32 条
  • [31] Sulkowski M., Mallolas J., Pol S., Et al., Effiacy and safety of the all-oral regimen MK-5172/MK-8742 with or without ribavirin for 12 weeks in GT1 HCV/HIV co-infected patients: the C-WORTHY study, J Hepatol, 60, (2014)
  • [32] Lawitz E., Hezode C., Gane E., Et al., Efficacy and safety of MK-5172 and MK-8742 with or without ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHY study, J Hepatol, 60, pp. S25-S26, (2014)
1234